Sotorasib
Overview
Sotorasib is an oral, small molecule inhibitor targeting the G12C mutant of the KRAS protein, which is present in various types of cancers. It is used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific KRAS mutations.
API suppliers (1)
Suppliers of Sotorasib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- TAPI NL BVNetherlands1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Sotorasib expires 15 Sept 2040 and exclusivity 16 Jan 2032. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Sotorasib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.